Aquestive Therapeutics (AQST) Other Accumulated Expenses (2017 - 2020)

Aquestive Therapeutics' Other Accumulated Expenses history runs 4 years deep, the most recent figure standing at $201000.0 for Q4 2020.

• In Q4 2020, Other Accumulated Expenses fell 17.28% year-over-year to $201000.0; the TTM figure through Dec 2020 stood at $201000.0 (down 17.28% YoY), while the FY2020 annual figure was $201000.0, down 17.28% from the prior year.
• Other Accumulated Expenses for Q4 2020 stood at $201000.0, down from $284000.0 in the prior quarter.
• The five-year high for Other Accumulated Expenses was $284000.0 in Q3 2020, with the low at $97000.0 in Q1 2020.
• The 4-year median for Other Accumulated Expenses is $215000.0 (2018), against an average of $213916.7.
• Peak annual rise in Other Accumulated Expenses reached 54.35% in 2020, while the deepest fall reached 49.48% in 2020.
• Aquestive Therapeutics' Other Accumulated Expenses stood at $225000.0 in 2017, then slipped by 8.0% to $207000.0 in 2018, then gained by 17.39% to $243000.0 in 2019, then declined by 17.28% to $201000.0 in 2020.
• Business Quant data shows AQST's Other Accumulated Expenses at $201000.0 in Q4 2020, $284000.0 in Q3 2020, and $223000.0 in Q2 2020.